(Q37939755)

25 August 2017

1 reference

title

Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline (English)

1 reference

25 August 2017

1 reference

ChEBI release 2020-05-28

Peter Jenner

1

1 reference

PubMed ID

21953831

25 August 2017

J William Langston

series ordinal

2

1 reference

PubMed ID

21953831

25 August 2017

language of work or name

English

0 references

publication date

23 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

26

1 reference

25 August 2017

13

1 reference

25 August 2017

2316-2323

1 reference

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

25 August 2017

1 reference

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics

21 January 2018

1 reference

Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

21 January 2018

1 reference

The delayed-start study in Parkinson disease: can't satisfy everyone

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

21 January 2018

1 reference

The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions

21 January 2018

1 reference

Biphasic and region-specific MAO-B response to aging in normal human brain.

21 January 2018

1 reference

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

21 January 2018

1 reference

Parkinson's syndrome and Parkinson's disease in mitochondrial disorders

21 January 2018

1 reference

Complex I, iron, and ferritin in Parkinson's disease substantia nigra

21 January 2018

1 reference

An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease.

21 January 2018

1 reference

Human complex I defects in neurodegenerative diseases

21 January 2018

1 reference

Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkinson's subject mitochondrial transfer

21 January 2018

1 reference

Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinson's Disease?

21 January 2018

1 reference

Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease

21 January 2018

1 reference

PINK1 is selectively stabilized on impaired mitochondria to activate Parkin

21 January 2018

1 reference

Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2.

21 January 2018

1 reference

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease

21 January 2018

1 reference

PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease

21 January 2018

1 reference

Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators

21 January 2018

1 reference

Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline

21 January 2018

1 reference

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

21 January 2018

1 reference

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

21 January 2018

1 reference

Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan

21 January 2018

1 reference

Neuroprotection by pharmacologic blockade of the GAPDH death cascade

21 January 2018

1 reference

Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis

21 January 2018

1 reference

Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol

21 January 2018

1 reference

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells

21 January 2018

1 reference

Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway

21 January 2018

1 reference

Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy

21 January 2018

1 reference

Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease

21 January 2018

1 reference

Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

21 January 2018

1 reference

Failure of the ubiquitin-proteasome system in Parkinson's disease

21 January 2018

1 reference

Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

21 January 2018

1 reference

Rasagiline is neuroprotective in a transgenic model of multiple system atrophy

21 January 2018

1 reference

N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2.

21 January 2018

1 reference

Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease

21 January 2018

1 reference

Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells

21 January 2018

1 reference

The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline

21 January 2018

1 reference

Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis

21 January 2018

1 reference

Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro

21 January 2018

1 reference

Protein degradation and protection against misfolded or damaged proteins

21 January 2018

1 reference

Altered proteasomal function in sporadic Parkinson's disease

21 January 2018

1 reference

Mitochondrial accumulation of polyubiquitinated proteins and differential regulation of apoptosis by polyubiquitination sites Lys-48 and -63

21 January 2018

1 reference

Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis

21 January 2018

1 reference

PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease

21 January 2018

1 reference

Glutathione in Parkinson's disease: a link between oxidative stress and mitochondrial damage?

21 January 2018

1 reference

Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group

21 January 2018

1 reference

Oxidative stress and Parkinson's disease.

21 January 2018

1 reference

Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle

21 January 2018

1 reference

The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

21 January 2018

1 reference

Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells

21 January 2018

1 reference

Oxidative stress and the pathogenesis of Parkinson's disease

21 January 2018

1 reference

Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis

21 January 2018

1 reference

Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism

21 January 2018

1 reference

L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse.

21 January 2018

1 reference

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial

21 January 2018

1 reference

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

21 January 2018

1 reference

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.23926

1 reference

25 August 2017

1 reference

PubMed ID

21953831